NewAmsterdam Pharma Company N.V. Weighted Average Fair Value At Measurement Date Share Options Granted
NewAmsterdam Pharma Company N.V. (NAMS) had Weighted Average Fair Value At Measurement Date Share Options Granted of EUR 4.55 as of 2023-06-30, per its 6-K filed 2023-08-07.
Financial Statements › Notes
ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted · last filed 2024-10-28
- 2023-06-30: Weighted Average Fair Value At Measurement Date Share Options Granted 4.55 EUR.
- 2022-12-31: Weighted Average Fair Value At Measurement Date Share Options Granted 4.20 EUR.
| Period end | Weighted Average Fair Value At Measurement Date Share Options Granted |
|---|---|
| 2023-06-30 | 4.55 EUR 6-K · filed 2023-08-07 |
| 2022-12-31 | 4.20 EUR 20-F/A · filed 2024-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |